Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Occult spinal dysraphism: lessons learned by retrospective analysis of 149 surgical cases about natural history, surgical indications, urodynamic testing, and intraoperative neurophysiological monitoring.
Valentini LG, Selvaggio G, Erbetta A, Cordella R, Pecoraro MG, Bova S, Boni E, Beretta E, Furlanetto M. Valentini LG, et al. Among authors: beretta e. Childs Nerv Syst. 2013 Sep;29(9):1657-69. doi: 10.1007/s00381-013-2186-5. Epub 2013 Sep 7. Childs Nerv Syst. 2013. PMID: 24013336
Piezoelectric Surgery for Dorsal Spine.
Franzini A, Legnani F, Beretta E, Prada F, DiMeco F, Visintini S, Franzini A. Franzini A, et al. Among authors: beretta e. World Neurosurg. 2018 Jun;114:58-62. doi: 10.1016/j.wneu.2018.03.026. Epub 2018 Mar 10. World Neurosurg. 2018. PMID: 29530686
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
Di Bartolomeo M, Pietrantonio F, Perrone F, Dotti KF, Lampis A, Bertan C, Beretta E, Rimassa L, Carbone C, Biondani P, Passalacqua R, Pilotti S, Bajetta E; Italian Trials in Medical Oncology Group. Di Bartolomeo M, et al. Among authors: beretta e. Target Oncol. 2014 Jun;9(2):155-62. doi: 10.1007/s11523-013-0283-8. Epub 2013 Jul 3. Target Oncol. 2014. PMID: 23821376 Clinical Trial.
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R; Italian Trials in Medical Oncology (I.T.M.O.) Group. Bajetta E, et al. Among authors: beretta e. Cancer. 2004 Jan 15;100(2):279-87. doi: 10.1002/cncr.11910. Cancer. 2004. PMID: 14716761 Free article. Clinical Trial.
202 results